Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

We evaluated the real-world efficacy and side effects of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. The medical records of patients receiving afatinib as a first-line therapy after National Health Insurance reimbursement between May 2014 and January 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Sheng-Kai, Hsieh, Min-Shu, Lee, Meng-Rui, Keng, Li-Ta, Ko, Jen-Chung, Shih, Jin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685763/
https://www.ncbi.nlm.nih.gov/pubmed/29163842
http://dx.doi.org/10.18632/oncotarget.19563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685763/
https://www.ncbi.nlm.nih.gov/pubmed/29163842
http://dx.doi.org/10.18632/oncotarget.19563

Ejemplares similares